Brett Garrison
{ Bio Portrait }

Brett Garrison is an associate in the firm’s Intellectual Property group in the Washington, DC office. He focuses on patent litigation in the pharmaceutical, biologic, and medical device industries. He has experience with all aspects of litigation, including two trials in cases brought under the Hatch-Waxman Act.

Professional Activities

  • American Bar Association, Section of Intellectual Property Law
  • American Intellectual Property Lawyers Association


Representative matters include:

  • Cosmo Techs. Ltd. v. Alvogen Pine Brook LLC, No. 15-cv-193-LPS (D. Del). Represented Alvogen and prevailed at trial in patent infringement litigation relating to a generic budesonide drug product (Uceris®). The Federal Circuit affirmed the judgment.
  • Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS & 14-cv-07252-JBS (D.N.J.). Represented Zydus and obtained denial of motion for temporary restraining order in patent infringement action relating to a generic aripiprazole drug product (Abilify®).
  • Omeros Corp. v. Par Sterile Products, LLC, No. 15-cv-773-RGA (D. Del). Represented Par in litigation involving multiple patents directed to a generic ketorolac/phenylephrine drug product (Omidria®). Secured favorable settlement after three-day bench trial.
  • Alcon Pharms. Ltd. v. Par Pharm. Inc., No. 15-cv-7240-PGS (D.N.J.). Represented Par in litigation involving multiple patents directed to a generic ciprofloxacin/dexamethasone drug product (Ciprodex®). Secured dismissal of case resulting in favorable settlement for Par.


  • JD, cum laude – Washington University School of Law (2014)
  • BA, Chemistry – New York University (2009)


  • District of Columbia
  • New York
  • US Court of Appeals for the Federal Circuit

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.